期刊
MOLECULAR THERAPY
卷 29, 期 11, 页码 3179-3191出版社
CELL PRESS
DOI: 10.1016/j.ymthe.2021.04.002
关键词
-
资金
- National Research Foundation of Korea, South Korea [2019R1C1C1005851]
- Technology Innovation Program [20012445]
- Ministry of Trade, Industry and Energy, South Korea
- National Research Foundation of Korea [2019R1C1C1005851] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
The CRISPR-Cas system shows potential in treating Duchenne muscular dystrophy (DMD), but challenges in developing more efficient therapeutic approaches and delivery methods remain.
The emerging clustered regularly interspaced short palindromic repeats (CRISPR)-mediated genome editing technologies have progressed remarkably in recent years, opening up the potential of precise genome editing as a therapeutic approach to treat various diseases. The CRISPR-CRISPR-associated (Cas) system is an attractive platform for the treatment of Duchenne muscular dystrophy (DMD), which is a neuromuscular disease caused by mutations in the DMD gene. CRISPR-Cas can be used to permanently repair the mutated DMD gene, leading to the expression of the encoded protein, dystrophin, in systems ranging from cells derived from DMD patients to animal models of DMD. However, the development of more efficient therapeutic approaches and delivery methods remains a great challenge for DMD. Here, we review various therapeutic strategies that use CRISPR-Cas to correct or bypass DMD mutations and discuss their therapeutic potential, as well as obstacles that lie ahead.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据